Immune system (SARS-CoV-2 spike and influenza hemagglutinin with Matrix-M adjuvant) (CIC vaccine target)

The target refers to the human immune system as it is modulated by a combination vaccine platform utilizing recombinant SARS-CoV-2 spike (S) protein and influenza hemagglutinin (HA) antigens, formulated with the Matrix-M adjuvant. This multi-antigen approach is designed to elicit protective immunity against both COVID-19 and seasonal influenza through the induction of neutralizing antibodies and cellular immune responses (Shinde et al., 2022, PubMed: 35439177). The Matrix-M adjuvant, a saponin-based formulation, enhances the immune response by promoting the recruitment of antigen-presenting cells to the injection site and facilitating a balanced Th1 and Th2 response (Stertman et al., 2023, PubMed: 37015421). By targeting the immune system with these specific antigens, the vaccine aims to reduce the global burden of respiratory infections during periods of viral co-circulation. Clinical evaluation focuses on the non-inferiority of the combination compared to standalone vaccines, monitoring hemagglutination inhibition (HAI) titers and anti-S IgG levels as primary correlates of protection. This strategy represents a significant advancement in vaccine technology, aiming to improve public health efficiency and patient compliance through a single-injection regimen.

Other names

COVID-19-Influenza Combination vaccineCIC vaccineNovavax CICSARS-CoV-2 rS + Influenza HA + Matrix-MNVX-CoV2373 plus Influenza HA

Induction of active immunity through the presentation of recombinant viral antigens (SARS-CoV-2 spike and influenza hemagglutinin) alongside a saponin-based adjuvant (Matrix-M) to stimulate B-cell and T-cell responses.